 SAN FRANCISCO, Aug. 03, 2020 GLOBE NEWSWIRE -- 89bio, Inc. Nasdaq: ETNB, a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the companys Chief Executive Officer, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference 2020 on Monday, August 10 , 2020 at 11:30 AM ET and the Canaccord Genuity 40th Annual Growth Conference on Wednesday, August 12, 2020 at 10:00 AM ET. The live and archived webcast of the presentation will be accessible from the companys website at The replay of the webcast will be available on the companys website.About 89bio89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The companys lead product candidate, BIO89-100, is being developed for the treatment of NASH and for the treatment of SHTG. BIO89-100 is a specifically engineered glycoPEGylated analog of FGF21 that is currently in a proof of concept Phase 1b2a clinical trial in patients with NASH or NAFLD and a high risk of NASH. 89bio is headquartered in San Francisco with operations in Herzliya, Israel. Visit 89bio.com for more information. Investor Contact: Ryan Martins Chief Financial Officer Contact: Lori Rosen LDR Communications 917-553-6808 